Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer ST. HELIER, Jersey & THE WOODLANDS, Texas–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and US Oncology Research are collaborating on PANOVA-3, …

Novocure to Present at Two Upcoming Investor Conferences

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences. Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in the 2018 Wedbush PacGrow Healthcare Conference on Aug. 15, 2018, in New York City. Mr. Groenhuysen’s presentation will begin at 12:45 p.m. EDT. Additionally, William Doyle, Novocure’s Executive Chairman, …

Novocure Announces Addition to Its Board of Directors

Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are extremely pleased to welcome Jeri to our board of …